Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility.

Van Nuffel AMT, Boudousquié C, Tuyaerts S.

Front Immunol. 2019 Aug 27;10:2032. doi: 10.3389/fimmu.2019.02032. eCollection 2019. No abstract available.

2.

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.

Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H.

BMC Cancer. 2019 May 28;19(1):506. doi: 10.1186/s12885-019-5676-3.

3.

A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer.

Tuyaerts S, Rombauts K, Everaert T, Van Nuffel AMT, Amant F.

Front Nutr. 2019 Jan 11;5:138. doi: 10.3389/fnut.2018.00138. eCollection 2018.

4.

ReDO_DB: the repurposing drugs in oncology database.

Pantziarka P, Verbaanderd C, Sukhatme V, Rica Capistrano I, Crispino S, Gyawali B, Rooman I, Van Nuffel AM, Meheus L, Sukhatme VP, Bouche G.

Ecancermedicalscience. 2018 Dec 6;12:886. doi: 10.3332/ecancer.2018.886. eCollection 2018.

5.

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G.

Ecancermedicalscience. 2015 Feb 24;9:513. doi: 10.3332/ecancer.2015.513. eCollection 2015.

6.

Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases.

Wilgenhof S, Corthals J, Van Nuffel AM, Benteyn D, Heirman C, Bonehill A, Thielemans K, Neyns B.

Cancer Immunol Immunother. 2015 Mar;64(3):381-8. doi: 10.1007/s00262-014-1642-8. Epub 2014 Dec 30.

PMID:
25548092
7.

Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory molecules.

Benteyn D, Van Nuffel AM, Wilgenhof S, Bonehill A.

Methods Mol Biol. 2014;1139:3-15. doi: 10.1007/978-1-4939-0345-0_1.

PMID:
24619665
8.

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.

Benteyn D, Anguille S, Van Lint S, Heirman C, Van Nuffel AM, Corthals J, Ochsenreither S, Waelput W, Van Beneden K, Breckpot K, Van Tendeloo V, Thielemans K, Bonehill A.

Mol Ther Nucleic Acids. 2013 Nov 19;2:e134. doi: 10.1038/mtna.2013.54.

9.

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.

Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B.

Ann Oncol. 2013 Oct;24(10):2686-93. doi: 10.1093/annonc/mdt245. Epub 2013 Jul 31.

10.

Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.

Pen JJ, De Keersmaecker B, Maenhout SK, Van Nuffel AM, Heirman C, Corthals J, Escors D, Bonehill A, Thielemans K, Breckpot K, Aerts JL.

J Immunol. 2013 Aug 15;191(4):1976-83. doi: 10.4049/jimmunol.1201008. Epub 2013 Jul 10.

11.

Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL).

Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

Biomed Res Int. 2013;2013:976383. doi: 10.1155/2013/976383. Epub 2013 Jan 3.

12.

Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy.

Van Nuffel AM, Wilgenhof S, Thielemans K, Bonehill A.

Oncoimmunology. 2012 Nov 1;1(8):1392-1394.

13.

Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, van der Bruggen P, Coulie PG, Neyns B, Thielemans K, Bonehill A.

Mol Ther. 2012 May;20(5):1063-74. doi: 10.1038/mt.2012.11. Epub 2012 Feb 28.

14.

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.

Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

J Immunol Methods. 2012 Mar 30;377(1-2):23-36. doi: 10.1016/j.jim.2011.12.010. Epub 2012 Jan 16.

PMID:
22269772
15.

Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.

Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

Cancer Immunol Immunother. 2012 Jul;61(7):1033-43. doi: 10.1007/s00262-011-1176-2. Epub 2011 Dec 10.

PMID:
22159452
16.

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B.

J Immunother. 2011 Jun;34(5):448-56. doi: 10.1097/CJI.0b013e31821dcb31.

PMID:
21577140
17.

Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases.

Wilgenhof S, Pierret L, Corthals J, Van Nuffel AM, Heirman C, Roelandt T, De Coninck A, Verfaillie G, Vandenbroucke F, Van Riet I, Bonehill A, Thielemans K, Neyns B.

Melanoma Res. 2011 Apr;21(2):152-9. doi: 10.1097/CMR.0b013e328343ece0.

PMID:
21317818
18.

Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.

Van Nuffel AM, Corthals J, Neyns B, Heirman C, Thielemans K, Bonehill A.

Methods Mol Biol. 2010;629:405-52. doi: 10.1007/978-1-60761-657-3_27.

PMID:
20387165
19.

Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases.

Pierret L, Baren NV, Bonehill A, Corthals J, Van Nuffel AM, Heirman C, Roelandt T, De Coninck A, Riet IV, Degreef E, Goossens A, Verfaillie G, Roseeuw D, Thielemans K, Neyns B.

Melanoma Res. 2009 Dec;19(6):385-90. doi: 10.1097/CMR.0b013e32832eabb5.

PMID:
19707165
20.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, François V, Colau D, van der Bruggen P, Neyns B, Thielemans K.

Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.

21.

Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.

Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, Neyns B, Thielemans K.

Mol Ther. 2008 Jun;16(6):1170-80. doi: 10.1038/mt.2008.77. Epub 2008 Apr 22.

Supplemental Content

Loading ...
Support Center